10-Q: Marizyme, Inc. Reports Q3 2024 Results, Cites Going Concern Uncertainty Amidst Restatement and Financial Constraints

Marizyme, Inc.'s Q3 2024 results reveal a net loss and highlight substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

Summary

• Marizyme, Inc. reported its financial results for the third quarter of 2024, showing a net loss of $1.96 million, compared to a net loss of $26.55 million for the same period in 2023.
• Revenue for the quarter was $0, a significant decrease from the $0.18 million reported in Q3 2023, attributed to a halt in inventory production due to financial constraints.
• For the nine months ended September 30, 2024, the company's net loss was $14.79 million, compared to $65.19 million for the same period in 2023.
• Revenue for the nine-month period was $32,855, a decrease from $495,248 in the prior year, also due to halted inventory production.
• The company's operating expenses decreased significantly, primarily due to lower professional fees, research and development costs, and other general and administrative expenses.
• Marizyme is facing a 'going concern' uncertainty due to recurring operating losses, negative cash flows, and an accumulated deficit of $170.32 million as of September 30, 2024.
• The company's ability to continue operations is dependent on raising additional capital and generating sufficient revenue.
• The company restated its previously issued unaudited interim condensed consolidated financial statements for the quarters ended March 31, 2024, and June 30, 2024, due to accounting errors related to debt/equity transactions.
• Management has identified a material weakness in internal control over financial reporting related to insufficient resources with appropriate knowledge and experience.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the net loss has decreased, the company faces significant financial challenges, including a 'going concern' uncertainty and a material weakness in internal control. The dependence on raising additional capital and the lack of revenue generation contribute to a negative sentiment.

Positives

• The net loss decreased significantly for both the three and nine months ended September 30, 2024, compared to the same periods in 2023.
• Operating expenses were substantially reduced, primarily due to lower professional fees and research and development costs.
• The company recognized a $0.4 million fair value gain from mark-to-market adjustments on contingent liabilities in Q3 2024.
• The company secured $1,250,000 in funding from Qualigen Therapeutics, Inc. in July 2024, providing temporary financial support.
• The company has secured additional funding of $1,027,400 in the form of short-term loans during the last quarter of the fiscal year 2024.

Negatives

• Revenue decreased significantly for both the three and nine months ended September 30, 2024, due to a halt in inventory production.
• The company has a significant accumulated deficit of $170.32 million as of September 30, 2024.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• A material weakness in internal control over financial reporting was identified, leading to a restatement of previous financial statements.
• The company has negative working capital of $29.12 million and limited cash on hand.
• The company incurred a $3.9 million loss on the extinguishment of Convertible Notes in the nine months ended September 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital, which may not be available on acceptable terms or at all.
• Failure to remediate the material weakness in internal control over financial reporting could lead to inaccuracies in financial statements and impair the company's ability to comply with reporting requirements.
• The company's reliance on sales of DuraGraft and the development of MAR-FG-001 may not generate sufficient revenue to achieve profitability.
• The company's dependence on third-party distributors for international sales exposes it to risks related to their performance and compliance with regulations.
• The company's limited cash resources may impact its ability to pursue its business strategy and continue as a going concern.

Future Outlook

The company expects to incur significant expenses and operating losses over the next several years and will need additional financing to support its continuing operations. The company will seek to fund its operations through public or private equity offerings, debt financings, government or other third-party funding, collaborations and licensing arrangements.

Management Comments

• Having received FDA authorization for marketing of DuraGraft, we are proceeding with our plans to commercialize DuraGraft in the United States and continue to generate international revenue growth from sales of DuraGraft.
• We will also seek to develop and commercialize additional applications for the technology underlying DuraGraft.

Industry Context

Marizyme operates in the medical technology sector, specifically focusing on cardiac care and vascular graft solutions. The company's DuraGraft product competes with other vascular conduit storage solutions, and its success depends on market adoption, regulatory approvals, and reimbursement rates. The company's focus on international markets and the development of new applications for its technology reflects a strategy to diversify revenue streams and expand its market presence.

Comparison to Industry Standards

• It is difficult to compare Marizyme's results directly to industry standards due to its unique product focus and stage of development.
• Comparable companies in the medical device space, such as CryoLife and Getinge, have significantly higher revenue and market capitalization.
• Marizyme's reliance on external funding and its 'going concern' status are atypical for established medical device companies.
• The company's focus on DuraGraft and its potential applications aligns with the broader trend of innovation in cardiac care and vascular surgery.
• However, its ability to compete effectively depends on securing additional funding, achieving regulatory milestones, and establishing a strong market presence.

Related Party Transactions

• At September 30, 2024, the Company owed an aggregate of $302,900 to related parties of the Company.
• For the three and nine months ended September 30, 2024, the Company incurred $277,000 and $882,000, respectively, for professional services rendered by related parties.
• During the three and nine months ended September 30, 2024, the Company also incurred $208,500 and $632,500 in compensation to Directors and Executive Officers for their services rendered, respectively.
• At September 30, 2024, the Company had $120,500 in prepaid royalties which had been classified as non-current in the condensed consolidated balance sheets.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need to raise additional capital.
• Employees may be affected by potential cost-cutting measures and the uncertainty surrounding the company's future operations.
• Customers and distributors may experience disruptions in product availability and support due to the company's financial constraints.
• Creditors face the risk of non-payment due to the company's 'going concern' uncertainty.

Next Steps

• The company intends to commercialize DuraGraft in the United States and continue to generate international revenue growth.
• The company will seek to develop and commercialize additional applications for the technology underlying DuraGraft.
• The company will continue to work on remediating the material weakness in internal control over financial reporting.
• The company expects to finance its cash needs through a combination of private and public equity offerings, debt financings, government or other third-party funding, and collaborations arrangements.

Key Dates